Cui Longzhu, Kiga Kotaro, Kondabagil Kiran, Węgrzyn Alicja
Division of Bacteriology, Department of Infection and Immunity, Jichi Medical University, Shimotsuke, Tochigi, 329-0498, Japan.
Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
Sci Rep. 2024 Oct 17;14(1):24404. doi: 10.1038/s41598-024-76427-5.
Phages are gaining attention for their ability to target drug-resistant bacteria, disrupt biofilms, and reach intracellular pathogens, offering promising alternatives to traditional antibiotics. The Collection discusses advances in phage therapy, including their application in vaccine development, cancer immunotherapy, and gene delivery systems. Key research gaps are identified, such as challenges related to phage stability, immune response, and regulatory hurdles. Despite the progress, phage therapy faces obstacles in maintaining phage viability, evading immune detection, and navigating complex regulatory frameworks. The articles collectively address these challenges and propose potential solutions to enhance the effectiveness and acceptance of phage-based treatments. By overcoming these barriers, bacteriophage research has the potential to revolutionize medical therapies, providing innovative approaches to some of the most pressing healthcare challenges today.
噬菌体因其能够靶向耐药细菌、破坏生物膜并作用于细胞内病原体而受到关注,为传统抗生素提供了有前景的替代方案。该论文集讨论了噬菌体疗法的进展,包括其在疫苗开发、癌症免疫疗法和基因递送系统中的应用。确定了关键的研究差距,例如与噬菌体稳定性、免疫反应和监管障碍相关的挑战。尽管取得了进展,但噬菌体疗法在维持噬菌体活力、逃避免疫检测以及应对复杂的监管框架方面仍面临障碍。这些文章共同探讨了这些挑战,并提出了潜在的解决方案,以提高基于噬菌体的治疗方法的有效性和可接受性。通过克服这些障碍,噬菌体研究有可能彻底改变医学治疗方法,为当今一些最紧迫的医疗保健挑战提供创新方法。